The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial

dc.contributor.author	García Campelo, María del Rosario
dc.date.accessioned	2017-06-07T07:36:21Z
dc.date.available	2017-06-07T07:36:21Z
dc.date.issued	2014
dc.identifier.issn	1078-0432
dc.identifier.uri	http://hdl.handle.net/20.500.11940/8447
dc.language.iso	eng
dc.title	The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial
dc.type	Artigo	es
dc.authorsophos	Costa, C.
dc.authorsophos	Molina, M. A.
dc.authorsophos	Drozdowskyj, A.
dc.authorsophos	Gimenez-Capitan, A.
dc.authorsophos	Bertran-Alamillo, J.
dc.authorsophos	Karachaliou, N.
dc.authorsophos	Gervais, R.
dc.authorsophos	Massuti, B.
dc.authorsophos	Wei, J.
dc.authorsophos	Moran, T.
dc.authorsophos	Majem, M.
dc.authorsophos	Felip, E.
dc.authorsophos	Carcereny, E.
dc.authorsophos	Garcia-Campelo, R.
dc.authorsophos	Viteri, S.
dc.authorsophos	Taron, M.
dc.authorsophos	Ono, M.
dc.authorsophos	Giannikopoulos, P.
dc.authorsophos	Bivona, T.
dc.authorsophos	Rosell, R.
dc.identifier.doi	10.1158/1078-0432.ccr-13-2233
dc.identifier.pmid	24493829
dc.identifier.sophos	15284
dc.issue.number	7
dc.journal.title	CLINICAL CANCER RESEARCH
dc.organization	Servizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de A Coruña - Complexo Hospitalario Universitario A Coruña::Oncoloxía médica
dc.page.initial	2001
dc.page.final	10
dc.rights.accessRights	openAccess
dc.typesophos	Artículo Original
dc.volume.number	20

Ficheros en el ítem

Ficheros	Tamaño	Formato	Ver
No hay ficheros asociados a este ítem.